Athersys

Athersys Share Buybacks

Delisted·Oct 1, 2026

The Share Buybacks of Athersys (ATHXQ) as of Nov 20, 2026 is 15.42 M USD. In the previous year, Share Buybacks was 39.15 M USD — a change of -60.61% (lower).

Share Buybacks

15.42 MUSD

YoY

-60.61%

Last updated:

Share Buybacks of Athersys is 2018 15.42 M USD. Share Buybacks of Athersys was 2017 39.15 M USD. It decreases by -60.61% lower compared to the previous year.

The Athersys Share Buybacks history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Share Buybacks
Date
Share Buybacks
Jan 1, 2014
20.56 M USD
Jan 1, 2015
11.29 M USD
Jan 1, 2016
4.19 M USD
Jan 1, 2017
39.15 M USD
Jan 1, 2018
15.42 M USD
The Athersys Share Buybacks history
YEARShare BuybacksYoY
15.42 MUSD-60.61%
39.15 MUSD+834.37%
4.19 MUSD-62.89%
11.29 MUSD-45.09%
20.56 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Athersys Stock analysis

What does Athersys do? Athersys, Inc. generates revenue through the development and commercialization of its MultiStem (invimestrocel) cell therapy, an allogeneic stem cell product candidate derived from adult bone marrow. The company focuses on late-stage clinical development for critical care, neurological conditions, inflammatory disorders, pulmonary conditions, and cardiovascular disease. Its lead product, MultiStem, is currently in Phase III clinical trials for ischemic stroke under the MASTERS-2 study. Athersys targets medical institutions and healthcare providers seeking innovative treatments for unmet medical needs in multiple disease areas. The company's primary product, MultiStem, is manufactured from human stem cells obtained from adult bone marrow and alternative tissue sources. It is designed to address conditions including critical care indications, neurological disorders, inflammatory and immune disorders, pulmonary conditions, and cardiovascular disease. Athersys conducts Phase III trials for ischemic stroke treatment, aiming to secure regulatory approval for broader market access. Revenue streams are expected to emerge post-approval through therapeutic product sales to hospitals and clinics. Athersys, Inc. operates in the biotechnology sector with a focus on regenerative medicine, leveraging its MultiStem platform to address unmet medical needs. The company's clinical development strategy centers on late-stage trials for ischemic stroke and other conditions, targeting healthcare providers and medical institutions as key customers. Commercialization of MultiStem will likely involve partnerships with healthcare systems for treatment protocols and patient access. Athersys is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Athersys stock

Share Buybacks of Athersys is 15.42 M USD in 2018.

Share Buybacks of Athersys changed from 39.15 M USD to 15.42 M USD, representing a -60.61% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Share Buybacks Athersys since 2006 – with annual values, charts, and detailed analysis.

Share buybacks represent the cash spent repurchasing the company's own shares. Buybacks reduce shares outstanding and can increase EPS.

Share Buybacks's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Share Buybacks's Athersys historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Athersys

All Key Metrics — Athersys